ENTA
Price
$7.40
Change
+$0.06 (+0.82%)
Updated
Jul 25 closing price
Capitalization
158.19M
15 days until earnings call
PRME
Price
$4.21
Change
-$0.14 (-3.22%)
Updated
Jul 25 closing price
Capitalization
566.23M
10 days until earnings call
Interact to see
Advertisement

ENTA vs PRME

Header iconENTA vs PRME Comparison
Open Charts ENTA vs PRMEBanner chart's image
Enanta Pharmaceuticals
Price$7.40
Change+$0.06 (+0.82%)
Volume$65.77K
Capitalization158.19M
Prime Medicine
Price$4.21
Change-$0.14 (-3.22%)
Volume$2.17M
Capitalization566.23M
ENTA vs PRME Comparison Chart in %
Loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTA vs. PRME commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Hold and PRME is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (ENTA: $7.40 vs. PRME: $4.21)
Brand notoriety: ENTA and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 39% vs. PRME: 57%
Market capitalization -- ENTA: $158.19M vs. PRME: $566.23M
ENTA [@Biotechnology] is valued at $158.19M. PRME’s [@Biotechnology] market capitalization is $566.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTA is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 2 bullish TA indicator(s).

  • ENTA’s TA Score: 4 bullish, 5 bearish.
  • PRME’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than PRME.

Price Growth

ENTA (@Biotechnology) experienced а -1.86% price change this week, while PRME (@Biotechnology) price change was +1.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

ENTA is expected to report earnings on Nov 24, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($566M) has a higher market cap than ENTA($158M). PRME YTD gains are higher at: 44.178 vs. ENTA (28.696). ENTA has higher annual earnings (EBITDA): -87.12M vs. PRME (-200M). ENTA has more cash in the bank: 193M vs. PRME (144M). ENTA has less debt than PRME: ENTA (58.7M) vs PRME (121M). ENTA has higher revenues than PRME: ENTA (64.5M) vs PRME (3.85M).
ENTAPRMEENTA / PRME
Capitalization158M566M28%
EBITDA-87.12M-200M44%
Gain YTD28.69644.17865%
P/E RatioN/AN/A-
Revenue64.5M3.85M1,677%
Total Cash193M144M134%
Total Debt58.7M121M49%
FUNDAMENTALS RATINGS
ENTA vs PRME: Fundamental Ratings
ENTA
PRME
OUTLOOK RATING
1..100
1440
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
5035
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (60) in the null industry is somewhat better than the same rating for ENTA (95) in the Biotechnology industry. This means that PRME’s stock grew somewhat faster than ENTA’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as ENTA (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's SMR Rating (97) in the Biotechnology industry is in the same range as PRME (98) in the null industry. This means that ENTA’s stock grew similarly to PRME’s over the last 12 months.

PRME's Price Growth Rating (35) in the null industry is in the same range as ENTA (50) in the Biotechnology industry. This means that PRME’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for PRME (100) in the null industry. This means that ENTA’s stock grew significantly faster than PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTAPRME
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 9 days ago
71%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 16 days ago
84%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCNAX47.120.49
+1.05%
Fidelity Advisor Consumer Discret A
ASQIX16.670.12
+0.73%
American Century Small Company Inv
JLVMX20.910.09
+0.43%
JPMorgan Large Cap Value R6
FVILX6.03N/A
N/A
Forester Value I
PKAAX13.60-0.04
-0.29%
PIMCO RAE US A

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ALEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+0.82%
ALEC - ENTA
42%
Loosely correlated
-1.68%
BEAM - ENTA
41%
Loosely correlated
+3.68%
SCPH - ENTA
40%
Loosely correlated
-4.11%
PRME - ENTA
38%
Loosely correlated
-3.22%
KRYS - ENTA
37%
Loosely correlated
-1.59%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-3.22%
CRSP - PRME
63%
Loosely correlated
-1.97%
RXRX - PRME
56%
Loosely correlated
+3.67%
BEAM - PRME
56%
Loosely correlated
+3.68%
CCCC - PRME
51%
Loosely correlated
-1.31%
CRBU - PRME
50%
Loosely correlated
-3.80%
More